Biocon Q3 results: Company posts net profit at Rs 660 crore
"A key milestone this quarter was the successful conclusion of the transition of the acquired business by Biocon Biologics and a pre-payment of USD 200 million towards the acquisition-related debt reduction," Biocon Executive Chairperson Kiran Mazumdar Shaw said.
)
Biotech firm Biocon on Thursday reported a consolidated net profit of Rs 660 crore for the third quarter ended December 31, 2023, on the back of robust sales. The company had reported a net loss of Rs 42 crore in the October-December period of last fiscal.
Total revenue rose to Rs 4,519 crore in the third quarter as against Rs 3,020 crore in the year-ago period, Biocon Ltd said in a statement.
"A key milestone this quarter was the successful conclusion of the transition of the acquired business by Biocon Biologics and a pre-payment of USD 200 million towards the acquisition-related debt reduction," Biocon Executive Chairperson Kiran Mazumdar Shaw said.
Steady market shares for key biosimilars in the US and EU were complemented by the emerging markets performance which saw a number of new product launches and tender wins, she added.
Catch the latest stock market updates here. For all other news related to business, politics, tech, sports, and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
10:33 PM IST
Should you buy, sell or hold L&T, Tata Power, Biocon, other stocks now?
Biocon gets 4 observations from USFDA for Bengaluru API facility
LIC raises stake in Biocon to 5.02%
Biocon Biologics got approval from the European Medicines Agency to manufacture biosimilar Bevacizumab in India